Fuming Qiu
Second Affiliated Hospital, Zhejiang University, School of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fuming Qiu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:48 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07848984 · Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast CancerSecond Affiliated Hospital, Zhejiang University, School of Medicine · not yet recruiting · Breast Neoplasms · principal investigator
- Ph1NCT07250386 · A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid TumorsSecond Affiliated Hospital, Zhejiang University, School of Medicine · recruiting · NSCLC (Advanced Non-small Cell Lung Cancer), Breast Cancer · principal investigator
- Ph1NCT06979674 · Study of ESG406 in Adults With Solid TumorsShanghai Escugen Biotechnology Co., Ltd · recruiting · Locally Advanced/Metastatic Solid Tumors · principal investigator
- Ph3NCT06523673 · Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung CancerSecond Affiliated Hospital, Zhejiang University, School of Medicine · recruiting · Metastatic Non-Small Cell Lung Cancer, NSCLC Stage IV, OligoProgressive Metastatic Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:48 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- 36 citationsRCR 6.8
- A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer.Nat Commun · 202231 citationsRCR 1.7
- 17 citationsRCR 0.6
- Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumors.Cell Rep Med · 202417 citationsRCR 1.4
- 15 citationsRCR 3.1
- Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial.Nat Commun · 20257 citationsRCR 1.4
- 5 citationsRCR 0.8
- Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer.Signal Transduct Target Ther · 2026